Keros Therapeutics (KROS) News Today $14.57 +0.41 (+2.90%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$14.38 -0.20 (-1.34%) As of 05/23/2025 06:23 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock KROS Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Keros Therapeutics, Inc. (NASDAQ:KROS) Stock Holdings Lifted by Millennium Management LLCMillennium Management LLC lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 53.3% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 878,159 shares of the company's stock after acquiring an aMay 25 at 3:47 AM | marketbeat.comBNP Paribas Financial Markets Invests $730,000 in Keros Therapeutics, Inc. (NASDAQ:KROS)BNP Paribas Financial Markets bought a new position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 46,110 shares of the company's stock, valued at approximatelMay 25 at 3:18 AM | marketbeat.comTwinbeech Capital LP Acquires 114,175 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Twinbeech Capital LP lifted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 742.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 129,553 shares of the company's stock after buying an additional 114,17May 24 at 4:53 AM | marketbeat.comNorthern Trust Corp Increases Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Northern Trust Corp increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 11.3% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 296,467 shares of the company's stockMay 24 at 3:18 AM | marketbeat.comADAR1 calls for Keros to release review results before voteMay 23 at 8:58 PM | uk.investing.comAnalysts Set Keros Therapeutics, Inc. (NASDAQ:KROS) PT at $37.00May 22 at 4:31 AM | americanbankingnews.comADAR1 Announces ISS Recommends Keros Therapeutics Stockholders WITHHOLD Votes from Directors Dr. Mary Ann Gray and Dr. Alpna SethMay 21, 2025 | prnewswire.comTema Etfs LLC Purchases Shares of 35,663 Keros Therapeutics, Inc. (NASDAQ:KROS)Tema Etfs LLC purchased a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 35,663 shares of the company's stock, valuedMay 20, 2025 | marketbeat.comKeros Therapeutics Highlights Commitment to Maximizing Stockholder ValueMay 19, 2025 | finance.yahoo.comKeros Therapeutics, Inc. (NASDAQ:KROS) Given Average Rating of "Moderate Buy" by AnalystsShares of Keros Therapeutics, Inc. (NASDAQ:KROS - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the fourteen ratings firms that are covering the stock, Marketbeat.com reports. Six equities research analysts have rated the stock with a hold rating and eight havMay 19, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Has $639,000 Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)The Manufacturers Life Insurance Company lifted its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 140.1% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 40,356 shares of the company's stock after buying an additionaMay 18, 2025 | marketbeat.comParkman Healthcare Partners LLC Sells 107,241 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Parkman Healthcare Partners LLC lessened its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 25.4% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 314,541 shares of the company's stock after selling 107,24May 16, 2025 | marketbeat.comOCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 105.6% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 50,897May 16, 2025 | marketbeat.comOccudo Quantitative Strategies LP Invests $1.64 Million in Keros Therapeutics, Inc. (NASDAQ:KROS)Occudo Quantitative Strategies LP acquired a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 103,40May 15, 2025 | marketbeat.comScotiabank Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $26.00Scotiabank cut their price objective on Keros Therapeutics from $41.00 to $26.00 and set a "sector outperform" rating on the stock in a report on Monday.May 14, 2025 | marketbeat.comKeros Therapeutics' (NASDAQ:KROS) Earnings May Just Be The Starting PointMay 14, 2025 | uk.finance.yahoo.comIntegral Health Asset Management LLC Purchases 250,000 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Integral Health Asset Management LLC lifted its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 125.0% in the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 450,000 shares of the company's stock after acquiring an additionalMay 14, 2025 | marketbeat.comBalyasny Asset Management L.P. Lowers Position in Keros Therapeutics, Inc. (NASDAQ:KROS)Balyasny Asset Management L.P. cut its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 32.0% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 221,391 shares of the company's stock after selling 104,043 shaMay 14, 2025 | marketbeat.comQ2 EPS Estimate for Keros Therapeutics Increased by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities researchers at HC Wainwright raised their Q2 2025 earnings estimates for shares of Keros Therapeutics in a note issued to investors on Thursday, May 8th. HC Wainwright analyst A. Fein now anticipates that the company will post earninMay 13, 2025 | marketbeat.comKeros Therapeutics price target lowered to $26 from $41 at ScotiabankMay 12, 2025 | msn.comADAR1 Capital Management Releases Investor Presentation Outlining Its Rationale for Withholding Votes From Directors Dr. Mary Ann Gray and Dr. Alpna SethMay 12, 2025 | prnewswire.comKeros Therapeutics Announces Participation at Bank of America 2025 Global Healthcare ConferenceMay 12, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Voya Investment Management LLCVoya Investment Management LLC reduced its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 83.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,488 shares of the company'sMay 12, 2025 | marketbeat.comLeerink Partnrs Has Negative Estimate for KROS Q2 EarningsKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Leerink Partnrs lowered their Q2 2025 EPS estimates for Keros Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($1.16) per share fMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Keros Therapeutics Lowered by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Equities research analysts at Wedbush decreased their Q2 2025 EPS estimates for Keros Therapeutics in a research note issued on Wednesday, May 7th. Wedbush analyst Y. Zhong now anticipates that the company will earn ($1.35) per share for theMay 11, 2025 | marketbeat.comQ2 EPS Forecast for Keros Therapeutics Decreased by AnalystKeros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Investment analysts at William Blair dropped their Q2 2025 earnings per share estimates for shares of Keros Therapeutics in a research report issued to clients and investors on Tuesday, May 6th. William Blair analyst M. Phipps now anticipatesMay 11, 2025 | marketbeat.comKeros Therapeutics Urges Stockholders to Support Board Nominees Amid ADAR1 Capital Management's Recent CommunicationsMay 10, 2025 | nasdaq.comWhat is Leerink Partnrs' Estimate for KROS FY2025 Earnings?Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) - Leerink Partnrs increased their FY2025 EPS estimates for shares of Keros Therapeutics in a report released on Tuesday, May 6th. Leerink Partnrs analyst T. Smith now anticipates that the company will post earnings per share of $0.94 for the yeMay 10, 2025 | marketbeat.comHC Wainwright Lowers Keros Therapeutics (NASDAQ:KROS) Price Target to $25.00HC Wainwright cut their price objective on Keros Therapeutics from $40.00 to $25.00 and set a "buy" rating for the company in a report on Thursday.May 10, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by DAFNA Capital Management LLCDAFNA Capital Management LLC increased its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 76.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 130,316 shares of the company's stock afterMay 10, 2025 | marketbeat.comKeros Therapeutics Shareholder ADAR1 Capital to Withhold Votes for Two Board MembersMay 9, 2025 | marketwatch.comKeros Therapeutics, Inc.: Keros Therapeutics Reports Recent First Quarter 2025 Financial ResultsMay 9, 2025 | finanznachrichten.deKeros Therapeutics, Inc.: Keros Reinforces Commitment to Maximizing Stockholder ValueMay 9, 2025 | finanznachrichten.deADAR1 Capital Management urges Keros Therapeutics for board changeMay 9, 2025 | msn.comKeros Therapeutics (KROS) to Release Quarterly Earnings on WednesdayKeros Therapeutics (NASDAQ:KROS) will be releasing its Q1 2025 earnings before the market opens on Wednesday, May 14. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-14-keros-therapeutics-inc-stock/)May 9, 2025 | marketbeat.comKeros Reinforces Commitment to Maximizing Stockholder ValueMay 8, 2025 | globenewswire.comADAR1 Capital Management Issues Open Letter to Keros Therapeutics StockholdersMay 8, 2025 | prnewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Braidwell LPBraidwell LP lifted its holdings in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 167.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 1,894,439 shares of the company's stock after acquiring an additional 1,18May 8, 2025 | marketbeat.comWhy I’m considering considering breaking my own investing rules for this value stockMay 6, 2025 | msn.comKeros Therapeutics Reports Recent First Quarter 2025 Financial ResultsMay 6, 2025 | globenewswire.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Sold by Alkeon Capital Management LLCAlkeon Capital Management LLC reduced its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 42.0% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,101,000 shares of the company's stock after sellMay 5, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Reduces Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Price T Rowe Associates Inc. MD lowered its stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 39.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 909,707 shareMay 5, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Acquired by Barclays PLCBarclays PLC increased its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 79.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 107,542 shares of the company's stockMay 5, 2025 | marketbeat.comBoxer Capital Management LLC Purchases New Shares in Keros Therapeutics, Inc. (NASDAQ:KROS)Boxer Capital Management LLC acquired a new stake in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 250,000 shares of the company's stMay 4, 2025 | marketbeat.comKeros Therapeutics, Inc. (NASDAQ:KROS) Shares Bought by Tower Research Capital LLC TRCTower Research Capital LLC TRC grew its position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 1,149.8% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,984 shares of the company's stock after acqMay 4, 2025 | marketbeat.comImplied Volatility Surging for Keros Therapeutics Stock OptionsMay 2, 2025 | theglobeandmail.comTCG Crossover Management LLC Reduces Stock Position in Keros Therapeutics, Inc. (NASDAQ:KROS)TCG Crossover Management LLC trimmed its position in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.5% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 550,000 shares of the cMay 1, 2025 | marketbeat.comDarwin Global Management Ltd. Has $26.71 Million Stock Holdings in Keros Therapeutics, Inc. (NASDAQ:KROS)Darwin Global Management Ltd. raised its holdings in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 10.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,687,135 shares of the company's stock after buying an adMay 1, 2025 | marketbeat.comEmerald Mutual Fund Advisers Trust Acquires 42,734 Shares of Keros Therapeutics, Inc. (NASDAQ:KROS)Emerald Mutual Fund Advisers Trust grew its stake in Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) by 37.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 155,347 shares of the company's stock after purchMay 1, 2025 | marketbeat.comLynx1 Capital Management LP Buys New Stake in Keros Therapeutics, Inc. (NASDAQ:KROS)Lynx1 Capital Management LP purchased a new position in shares of Keros Therapeutics, Inc. (NASDAQ:KROS - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The firm purchased 544,001 shares of the company's stock, valued at approxiApril 29, 2025 | marketbeat.com Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address KROS Media Mentions By Week KROS Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. KROS News Sentiment▼1.250.77▲Average Medical News Sentiment KROS News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. KROS Articles This Week▼105▲KROS Articles Average Week Get Keros Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for KROS and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Vericel News Arrowhead Pharmaceuticals News Belite Bio News Apellis Pharmaceuticals News NewAmsterdam Pharma News Denali Therapeutics News Ascentage Pharma Group International News Harmony Biosciences News Kymera Therapeutics News CG Oncology News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:KROS) was last updated on 5/25/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Keros Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Keros Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy KROS Stock Free KROS Stock Alerts